• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·060280.KQ
Share

Curexo Inc. Stocks

₩ 8130Last Updated 18.09.2026

Issuer Rating

2/7
Performance

Poor

Risk

Moderate

Recommendation

Sell

Market Cap

₩ 248.18M

₩ 8130
Key Takeaways

Risk factor

High price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

CUREXO, Inc. specializes in the creation and distribution of medical technology. The company's activities are organized across three primary divisions: Medical Robot, Implant, and Trade. Its Medical Robot segment focuses on advanced robotic systems designed for surgical procedures, such as joint replacement and spinal operations, in addition to rehabilitation robots and other specialized medical devices. The Implant division is dedicated to manufacturing artificial joint prostheses and a range of other internal body implants. A unique aspect of the company is its Trade division, which manages the import and sale of food products. CUREXO was established on February 29, 1992, and its main offices are situated in Seoul, South Korea.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

23.09.2026 14:28

Is the small-cap rally coming to an end? 4 rules for picking stocks as the Fed raises rates

23.09.2026 14:02

Shares of Chinese AI developers fell following reports of an investigation into DeepSeek and Moonshot

23.09.2026 13:32

Apollo has restricted withdrawals from its private lending fund for the third consecutive time

23.09.2026 13:01

The crisis involving investment funds in Turkey is not over yet. What should investors keep an eye on?

23.09.2026 12:31

Oil is heading for its longest losing streak of the year. Traders' bets on a decline are at a peak.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026